topic

324 Allogeneic CAR T cells targeting Liv-1 for breast cancer
Lauren Zakas, Minh Pham, Laura Bartle, Zejun Li, Kelly Maeng, Luke Hanley, Avanti Ganpule, Jason Sagert, Jonathan Terrett, Demetrios Kalaitzidis

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A368; DOI: 10.1136/jitc-2023-SITC2023.0324
325 Armored STEAP2 CAR-T (AZD0754) alone and in combination with enzalutamide demonstrates anti-tumor activity across a range of STEAP2 expressing prostate cancer PDX models
Peter Zanvit, Kelly McGlinchey, Christine Fazenbaker, Weichuan Luo, Jessica Pezold, Clare Hoover, Mark Cobbold, Gordon Moody, Emily Bosco

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A369; DOI: 10.1136/jitc-2023-SITC2023.0325
326 Abstract withdrawn
Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A370-A372; DOI: 10.1136/jitc-2023-SITC2023.0326
327 Humanized mouse models for characterizing growth and tissue infiltration of luciferase-expressing AML cell lines
Emilie Bayon, Bastien Wolff, Arije Mersni, Audrey Wetzel, Jade Villé, Federico Simonetta, Kiave-Yune Ho Wand Yin

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A373; DOI: 10.1136/jitc-2023-SITC2023.0327
328 Preclinical analyses and proof of concept clinical study of Epstein Barr Virus (EBV) specific genetically modified T cells against EBV associated malignancies
Xin-Feng Chen, Dan Wang, Jianmin Huan, Xudong Zhang, Ling Li, XI Zhang, Renata Stripecke, Scott Burrows, Deping Han, Mingzhi Zhang, Yi Zhang

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A374-A375; DOI: 10.1136/jitc-2023-SITC2023.0328
329 Redirecting NK cell cytotoxicity by innate cell engagers: a differentiated and innovative approach compared to CAR-NK cells
Sonya Ioana Ciulean, Julia Uhlig, Thea Eichenberg, Joe Fischer, Michael Albers, Christian Breunig, Jan Schmollinger, Jens Pahl, Ivica Fucek, Christoph Bach, Paul Franz, Anna Dünkel, Stephan Fricke, Thomas Grunwald, Ulrike Köhl, Joachim Koch

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A376; DOI: 10.1136/jitc-2023-SITC2023.0329
330 Combination therapy with stem cell derived natural killer cells and monoclonal antibodies leads to potent ADCC through engagement of endogenouse CD16
Anna-Maria Georgoudaki, Nina Lamers-Kok, Amanda van Vliet, Didem Özkazanc, Denise Vodegel, Daniëlle Steenmans, Monica Raimo, Adil Duru, Jan Spanholtz

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A377; DOI: 10.1136/jitc-2023-SITC2023.0330
331 Functional enhancement of T cells by the co-expression of IL-7 and dominant-negative TGFβRII
Zhihong Huang, Mingyu Liu, Deping Han, Jean Paul Thiery, Xi Zhang

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A378-A379; DOI: 10.1136/jitc-2023-SITC2023.0331
332 WU-NK-101, an off-the-shelf memory NK cell product, reverses immune checkpoint inhibitor (ICB) resistance with synergistic anti-tumor activity
Tom Leedom, Alexander Hamil, Basia Muz, Lena Luukkonen, John Muth, Melissa Tran, Xia-Ha Li, Kristann Magee, Jayakmar Vadakekolathu, Sergio Rutella, Ayman Kabakibi, Matthew L Cooper, Jan Davidson-Moncada

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A380; DOI: 10.1136/jitc-2023-SITC2023.0332
333 Abstract withdrawn
Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A381-A382; DOI: 10.1136/jitc-2023-SITC2023.0333

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages